Global kidney crisis: 50% of kidney failure stems from non-diabetic causes—systemic solutions needed beyond diabetes-centric drug narratives
Original framing: “[Comment] Finerenone: kidney protection beyond type 2 diabetes” — The Lancet
Scientific evidence supports the multifactorial etiology of CKD, with environmental toxins (e.g., cadmium, aristolochic acid) and occupational exposures (e.g., silica, solvents) contributing significantly to disease progression. Meta-analyses show that 30-40% of CKD cases in low-income countries are linked to agrochemical exposure, yet these data are sidelined in favor of diabetes-centric research. The scientific community’s bias toward drug trials over environmental epidemiology reflects funding priorities, not objective risk assessment.
The Lancet’s focus on finerenone exemplifies how pharmaceutical narratives dominate health discourse, obscuring the systemic drivers of kidney disease: industrial pollution, occupational hazards, and healthcare inequities.
This diabetes-centric framing serves the interests of drug developers and insurers while depoliticizing disease causation, particularly for the 50% of patients whose kidney failure stems from non-diabetic causes. Cross-cultural perspectives—from Ayurveda to Afro-Brazilian traditions—offer holistic, preventive models that challenge Western reductionism, yet these are systematically marginalized. The marginalized voices of Black, Indigenous, and low-income communities, who bear the brunt of environmental racism, are erased in favor of marketable solutions. A systemic response requires dismantling the profit motives of dialysis corporations, enforcing corporate accountability for toxic exposures, and integrating traditional knowledge with evidence-based care. The future of kidney health lies not in another blockbuster drug, but in ecological restoration, community empowerment, and structural justice.